Evidence-Based Answers

Evidence Central™ is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research.


Evidence Central for Mobile Devices

Evidence Central iOS iPhone iPad Android

Evidence Central from Unbound Medicine, available for iOS® and Android™, is optimized for each platform and features superior navigation, so answers are easy to find at the bedside or anywhere they’re needed. Learn More

Word of the Day

No added benefit beyond 30 days with enoxaparin after fibrinolysis for STEMI

Clinical Question:
Does the use of enoxaparin as compared with unfractionated heparin after fibrinolysis for ST-segment elevation myocardial infarction improve long-term mortality and morbidity?

Bottom Line:
Although a previous study showed that the use of enoxaparin as compared with unfractionated heparin (UFH) decreases short-term risk of death or myocardial infarction in patients with ST-segment elevation myocardial infarction (STEMI) who receive fibrinolysis, there is no additional benefit beyond the initial 30 days. (LOE = 1b)

Morrow DA, Antman EM, Fox KA, et al, for the ExTRACT-TIMI 25 Investigators. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. Eur Heart J 2010;31(17):2097-2102.  [PMID:20400762]

Study Design:
Randomized controlled trial (nonblinded)



Inpatient (any location) with outpatient follow-up

Previous data from the ExTRACT-TIMI 25 trial showed reduced 30-day risk of death or myocardial infarction with the use of enoxaparin as compared with UFH following fibrinolysis for STEMI. In this industry-sponsored trial, investigators report 1-year outcomes of the 2 strategies. Adults presenting with STEMI within 6 hours of symptom onset without contraindication to fibrinolysis, hemodynamic instability, or known renal insufficiency were eligible. All participants were treated with aspirin and a fibrinolytic, followed by either UFH (n = 10,122) or enoxaparin (n = 10,153) for a minimum of 48 hours until completion of successful coronary revascularization, hospital discharge, or a maximum of 8 days. The 2 groups were well balanced at baseline. Patients had a median age of 59 years and 75% were male. Analysis was by intention to treat, and follow-up through 1 year was available for 99% of the group. The primary end point of death or nonfatal recurrent myocardial infarction at 1 year was reduced with the use of enoxoparin as compared with UFH (15.8% vs 17.0%; hazard ratio = 0.92; 95% CI, 0.86-0.98; P = .01). However, this was primarily driven by a reduction in recurrent myocardial infarction with no difference in mortality at 1 year. Additionally, analyses from 30 days to 1 year revealed that reduction in both death and myocardial infarction occurred early on with no additional benefit after the initial 30-day period.


Site Licenses

Site license

Site Licenses are available for schools, universities, hospitals, government agencies, and companies. For more information, contact us.